Novel Platforms for the Development of a Universal influenza vaccine

Arun Kumar, Trine Sundebo Meldgaard, Sylvie Bertholet*

*Corresponding author for this work

    Research output: Contribution to journalJournal articleResearchpeer-review

    339 Downloads (Pure)


    Despite advancements in immunotherapeutic approaches, influenza continues to cause severe illness, particularly among immunocompromised individuals, young children, and elderly adults. Vaccination is the most effective way to reduce rates of morbidity and mortality caused by influenza viruses. Frequent genetic shift and drift among influenzavirus strains with the resultant disparity between circulating and vaccine virus strains limits the effectiveness of the available conventional influenza vaccines. One approach to overcome this limitation is to develop a universal influenza vaccine that could provide protection against all subtypes of influenza viruses. Moreover, the development of a novel or improved universal influenza vaccines may be greatly facilitated by new technologies including virus-like particles, T-cell-inducing peptides and recombinant proteins, synthetic viruses, broadly neutralizing antibodies, and nucleic acid-based vaccines. This review discusses recent scientific advances in the development of next-generation universal influenza vaccines.
    Original languageEnglish
    Article number600
    JournalFrontiers in Immunology
    Number of pages14
    Publication statusPublished - 2018


    • Influenza
    • Hemagglutinin
    • Virus-like particles
    • Universal flu vaccine
    • Neutralizing antibodies
    • Vaccination strategies
    • Functional antibody responses

    Fingerprint Dive into the research topics of 'Novel Platforms for the Development of a Universal influenza vaccine'. Together they form a unique fingerprint.

    Cite this